Proposed cancellation

Summary by AI BETAClose X

Allergy Therapeutics proposes to cancel its AIM admission and re-register as a private limited company, subject to shareholder approval at the AGM on 14 December 2026; if approved the Cancellation will be effective at 7:00 a.m. on 22 December 2026 and re-registration is expected in the week commencing 11 January 2027. The Board cites AIM costs in excess of £1 million per annum and limited liquidity (public float ~9%, average daily volume ~444,544 shares or ~0.01% of issued capital) as key reasons. Controlling shareholders SkyGem and Southern Fox hold 87.98% and have committed to support the proposals, while Directors hold 9,167,707 shares (≈0.14%). A Matched Bargain Facility with a 1.5% trading fee will operate for at least 12 months.

Disclaimer*

UK 100

Latest directors dealings